EGFR and lung adenocarcinoma: However, the EGFR-TKIs sensitive mutation rate of 41.8% in lung adenocarcinoma is lower than the rate of 66.3% in a study with a cohort in Southern China [16], but much higher than the mutation rate of 7.5% in the study with a cohort of Northern European populations [27, 28].